Staphylococcus aureus is a highly successful human pathogen that has evolved in response to human immune pressure. The common USA300 methicillin-resistant S. aureus (MRSA) strains express a number of toxins, such as Panton-Valentine leukocidin and LukAB, that have specificity for human receptors. Using nonobese diabetic (NOD)-scid IL2Rγ null (NSG) mice reconstituted with a human hematopoietic system, we were able to discriminate the roles of these toxins in the pathogenesis of pneumonia. We demonstrate that expression of human immune cells confers increased severity of USA300 infection. The expression of PVL but not LukAB resulted in more-severe pulmonary infection by the wild-type strain (with a 30-fold increase in the number of colony-forming units/mL; P < .01) as compared to infection with the lukS/F-PV (Δpvl) mutant. Treatment of mice with anti-PVL antibody also enhanced bacterial clearance. We found significantly greater numbers (by 95%; P < .05) of macrophages in the airways of mice infected with the Δpvl mutant compared with those infected with the wild-type strain, as well as significantly greater expression of human tumor necrosis factor and interleukin 6 (84% and 51% respectively; P < .01). These results suggest that the development of humanized mice may provide a framework to assess the contribution of human-specific toxins and better explore the roles of specific components of the human immune system in protection from S. aureus infection.Keywords. Staphylococcus aureus; pneumonia; lung; respiratory; host-pathogen; humanized; mouse model; PVL; Panton-Valentine leukocidin.Staphylococcus aureus is a well-recognized human pathogen associated with infection in diverse hosts; it is an important cause of healthcare-associated infection but also a major cause of morbidity and mortality in healthy patients with no factors predisposing them to infection. Nasal colonization with S. aureus is associated with subsequent infection and occurs in up to 30% of unselected individuals [1,2]. Yet, despite the prevalence of S. aureus in the general population, the specific correlates of protective immunity against staphylococcal infection are not well defined.A number of S. aureus virulence factors, including several bicomponent toxins, are specific for human receptors [3,4]. One of the first of these human-specific toxins to be fully characterized was Panton-Valentine leukocidin (PVL), which targets neutrophils, macrophages, and monocytes [5,6]. Although epidemiologically linked to severe infection in humans [7,8], the PVL null mutant (lukS/lukF) did not consistently demonstrate the expected phenotype in murine models [5,[8][9][10][11][12][13], although it was significantly attenuated in rabbit models of pneumonia [5]. The molecular basis for this discrepancy was ascribed to the high human (and rabbit) specificity for the PVL receptors, C5aR and C5L2 [14]. Additional toxins, LukAB and HlgCB, have also been shown to have high specificity to the human forms of the receptors, CD11b and C5aR, respectively [4,14,15]. These ...